Keith Tennison
About Keith Tennison
Keith Tennison serves as the Vice President of Market Access at KalVista Pharmaceuticals, Inc. since 2023, bringing extensive experience from previous roles at UCB, Pfizer, and Sunovion Pharmaceuticals, where he specialized in market access strategy and healthcare management.
Work at KalVista Pharmaceuticals
Keith Tennison serves as the Vice President of Market Access at KalVista Pharmaceuticals, Inc., a role he has held since 2023. Based in Cambridge, Massachusetts, he is responsible for overseeing market access strategies and initiatives. His position involves developing and implementing approaches that facilitate access to KalVista's pharmaceutical products in the market.
Previous Experience in Market Access
Before joining KalVista Pharmaceuticals, Keith Tennison worked at UCB as the Head of Market Access Strategy for Epilepsy and Rare Syndromes from 2021 to 2023. His career also includes significant roles at Sunovion Pharmaceuticals, where he held various positions including Director of Health System Accounts and Director of Business Operations in Market Access. His extensive background in market access spans over two decades, including a notable tenure at Pfizer.
Education and Expertise
Keith Tennison earned a Bachelor of Science degree in Biology from Lamar University, completing his studies from 1994 to 1998. He later obtained a Master of Business Administration in Healthcare Management from the University of Phoenix between 2002 and 2004. His expertise includes developing digital healthcare solutions and value-based offerings, focusing on improving value, outcomes, and population health strategies.
Leadership in Product Launch Programs
Throughout his career, Keith Tennison has led multiple product launch programs for first-in-class therapeutics. These initiatives required innovative payer and provider access and distribution solutions, showcasing his ability to navigate complex healthcare ecosystems. His leadership in these programs reflects his commitment to enhancing market access for new therapeutic options.